Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Jul 27;9(1):266.
doi: 10.1038/s41420-023-01558-z.

An overview of arsenic trioxide-involved combined treatment algorithms for leukemia: basic concepts and clinical implications

Yanan Jiang #  1   2 , Xiuyun Shen #  3 , Fengnan Zhi  3 , Zhengchao Wen  3 , Yang Gao  4 , Juan Xu  5 , Baofeng Yang  6   7   8 , Yunlong Bai  9   10
Affiliations
Review

An overview of arsenic trioxide-involved combined treatment algorithms for leukemia: basic concepts and clinical implications

Yanan Jiang et al. Cell Death Discov. .

Abstract

Arsenic trioxide is a first-line treatment drug for acute promyelocytic leukemia, which is also effective for other kinds of leukemia. Its side effects, however, limit its clinical application, especially for patients with complex leukemia symptoms. Combination therapy can effectively alleviate these problems. This review summarizes the research progress on the combination of arsenic trioxide with anticancer drugs, vitamin and vitamin analogs, plant products, and other kinds of drugs in the treatment of leukemia. Additionally, the new progress in arsenic trioxide-induced cardiotoxicity was summarized. This review aims to provide new insights for the rational clinical application of arsenic trioxide.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Fig. 1
Fig. 1. The combined drugs with arsenic trioxide in the treatment of leukemia.
The figure summarizes the research progress of arsenic trioxide combined with anticancer drugs, vitamins and vitamin analogs, plant products and other kind of drugs in the treatment of leukemia.
See this image and copyright information in PMC

References

    1. Soignet SL, Maslak P, Wang ZG, Jhanwar S, Calleja E, Dardashti LJ, et al. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N Engl J Med. 1998;339:1341–8. doi: 10.1056/NEJM199811053391901. - DOI - PubMed
    1. Shen ZX, Chen GQ, Ni JH, Li XS, Xiong SM, Qiu QY, et al. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood. 1997;89:3354–60. doi: 10.1182/blood.V89.9.3354. - DOI - PubMed
    1. Shigeno K, Naito K, Sahara N, Kobayashi M, Nakamura S, Fujisawa S, et al. Arsenic trioxide therapy in relapsed or refractory Japanese patients with acute promyelocytic leukemia: updated outcomes of the phase II study and postremission therapies. Int J Hematol. 2005;82:224–9. doi: 10.1532/IJH97.05044. - DOI - PubMed
    1. Huang SY, Chang CS, Tang JL, Tien HF, Kuo TL, Huang SF, et al. Acute and chronic arsenic poisoning associated with treatment of acute promyelocytic leukaemia. Br J Haematol. 1998;103:1092–5. doi: 10.1046/j.1365-2141.1998.01079.x. - DOI - PubMed
    1. Mathews V, Desire S, George B, Lakshmi KM, Rao JG, Viswabandya A, et al. Hepatotoxicity profile of single agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia, its impact on clinical outcome and the effect of genetic polymorphisms on the incidence of hepatotoxicity. Leukemia. 2006;20:881–3. doi: 10.1038/sj.leu.2404165. - DOI - PubMed